• A
  • |
  • A
  • Text size

Names Under Consideration

USAN Council's statement on the use of USAN as domain names:

A name published by the United States Adopted Names (USAN) Program in the USP Dictionary of USAN and International Nonproprietary Names, and on the United States Adopted Names Web site, shall be the effective equivalent of an intellectual property right on the part of the relevant entities.

Comments or protests should be addressed to Stephanie Shubat, USAN Program Director, American Medical Association, 330 North Wabash Avenue, Suite 39300, Chicago, Ill. 60611, or sent via email to USAN@ama-assn.org.

In order to ensure your "Under Consideration" USAN domain name is available, USAN applicants should consider purchasing the .com, .net, and .org domain names of your USAN under consideration. The optimal time to do this is when you receive the letter from the USAN Program informing you of the USAN Council's naming decision.

The following list of names for the drugs described are "under consideration" by the USAN Council:

September 2016

biropepimut-s antineoplastic
diroximel fumarate treatment of multiple sclerosis
efizonerimod antineoplastic
ingenol disoxate treatment of actinic keratosis
omirsen treatment of hematologic malignancies
prexigbersen treatment of hematologic malignancies, inflammation and autoimmune disease
relatlumab treatment of cancer

August 2016

gosuranezumab treatment of progressive supranuclear palsy (PSP)
otamilast treatment of atopic dermatitis, topical agent
rosuranezumab treatment of progressive supranuclear palsy (PSP)

July 2016

bravilizumab treatment of paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS)
crenigacestat antineoplastic
cofetuzumab treatment of oncology
emplumab treatment of cancer
etsantuzumab treatment of oncology
evispectinib treatment of cancer
hafnium oxide radiation sensitizer
metamide methyl fumarate treatment of multiple sclerosis, psoriasis
mirikizumab treatment of autoimmune diseases
otanvimilast treatment of atopic dermatitis, topical agent
pegilodecakin treatment of advanced solid tumors
ralaniten treatment of prostate cancer
rasdelumab nesotigen treatment of malignancies expressing NY-ESO-1
setocabtagene pirtaretroleucel treatment of leukemia
talditermant alfa treatment of duchenne muscular dystrophy, spinal muscular atrophy, ALS
tibulizumab treatment of autoimmune disorders
tracaronase treatment of spinal cord injury
vesbictinib antineoplastic